beeldscherm schreef op 9 februari 2018 09:58:
Given lanadelumab’s compelling efficacy and advantage over existing treatments, Deutsche Bank analysts said they expected it to dominate and significantly expand the current $1.8 billion HAE prophylaxis market.
The U.S. Food and Drug Administration has already granted the drug - which Shire acquired through its $5.9 billion buyout of Dyax in 2016 - “orphan drug” and “breakthrough therapy” designations.
Shire said it planned to submit a U.S. marketing application for lanadelumab by late 2017/early 2018. The company also expects to submit an EU application in the first half of next year, pending regulatory discussions.
1.8 Miljard markt....zeg ietsjes meer als 1/3 v Ruconest zit je toch al snel op een 700Miljoen(onderkant)
o ja,
Shire PLC
LON: SHP - 9 Feb, 08:56 GMT
3.068,00GBXPrice decrease25,50 (0,82%)
zou zomaar meer kunnen worden...